Literature DB >> 17301132

tRNA isoacceptor preference prior to retrovirus Gag-Pol junction links primer selection and viral translation.

Matthew T Palmer1, Richard Kirkman, Barry R Kosloff, Peter G Eipers, Casey D Morrow.   

Abstract

An essential step in the replication of all retroviruses is the capture of a cellular tRNA that is used as the primer for reverse transcription. The 3'-terminal 18 nucleotides of the tRNA are complementary to the primer binding site (PBS). Moloney murine leukemia virus (MuLV) preferentially captures tRNA(Pro). To investigate the specificity of primer selection, the PBS of MuLV was altered to be complementary to different tRNAs. Analysis of the infectivity of the virus and stability of the PBS following in vitro replication revealed that MuLV prefers to select tRNA(Pro), tRNA(Gly), or tRNA(Arg). Previous studies from our laboratory have suggested that tRNA primer capture is coordinated with translation. Coincidentally, a cluster of proline, arginine, and glycine precedes the Gag-Pol junction of MuLV. Human immunodeficiency virus type 1 (HIV-1), which prefers tRNA(3)(Lys) as the primer, can be forced to utilize tRNA(Met), tRNA(1,2)(Lys), tRNA(His), or tRNA(Glu), although these viruses replicate poorly. Codons for methionine, lysine, histidine, or glutamic acid are found prior to the Gag-Pol frameshift site. HIV-1 was mutated so that the 5 lysine codons prior to the Gag-Pol frameshift region were specific for tRNA(1,2)(Lys). HIV-1 forced to use tRNA(1,2)(Lys) as the primer, with the mutation of codons specific for tRNA(1,2)(Lys) prior to the Gag-Pol junction, had enhanced infectivity and replicated similarly to the wild-type virus. The results demonstrate that codon preference prior to the Gag-Pol junction influences primer selection and suggest a coordination of Gag-Pol synthesis and acquisition of the tRNA primer required for retrovirus replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301132      PMCID: PMC1900135          DOI: 10.1128/JVI.02643-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription.

Authors:  F Brulé; G Bec; G Keith; S F Le Grice; B P Roques; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.

Authors:  A Khorchid; H Javanbakht; S Wise; R Halwani; M A Parniak; M A Wainberg; L Kleiman
Journal:  J Mol Biol       Date:  2000-05-26       Impact factor: 5.469

3.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Reverse transcription of avian sarcoma virus RNA into DNA might involve copying of the tRNA primer.

Authors:  J M Taylor; T W Hsu
Journal:  J Virol       Date:  1980-01       Impact factor: 5.103

Review 5.  Form and function of retroviral proviruses.

Authors:  H E Varmus
Journal:  Science       Date:  1982-05-21       Impact factor: 47.728

6.  Structure, variation and synthesis of retrovirus long terminal repeat.

Authors:  H M Temin
Journal:  Cell       Date:  1981-11       Impact factor: 41.582

7.  RNA-directed DNA synthesis in Moloney murine leukemia virus: interaction between the primer tRNA and the genome RNA.

Authors:  G Peters; J E Dahlberg
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

8.  The crystal structure of HIV reverse-transcription primer tRNA(Lys,3) shows a canonical anticodon loop.

Authors:  P Bénas; G Bec; G Keith; R Marquet; C Ehresmann; B Ehresmann; P Dumas
Journal:  RNA       Date:  2000-10       Impact factor: 4.942

9.  Binding of tRNA to reverse transcriptase of RNA tumor viruses.

Authors:  A Panet; H Berliner
Journal:  J Virol       Date:  1978-05       Impact factor: 5.103

10.  Isolation of recombinant DNA clones carrying complete integrated proviruses of Moloney murine leukemia virus.

Authors:  L Bacheler; H Fan
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

View more
  7 in total

Review 1.  Role of host tRNAs and aminoacyl-tRNA synthetases in retroviral replication.

Authors:  Danni Jin; Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

2.  Solution nuclear magnetic resonance analyses of the anticodon arms of proteinogenic and nonproteinogenic tRNA(Gly).

Authors:  Andrew T Chang; Edward P Nikonowicz
Journal:  Biochemistry       Date:  2012-04-18       Impact factor: 3.162

3.  Forced selection of tRNA(Glu) reveals the importance of two adenosine-rich RNA loops within the U5-PBS for SIV(smmPBj) replication.

Authors:  Maureen C Kelly; Barry R Kosloff; Casey D Morrow
Journal:  Virology       Date:  2007-06-01       Impact factor: 3.616

Review 4.  The queuine micronutrient: charting a course from microbe to man.

Authors:  Claire Fergus; Dominic Barnes; Mashael A Alqasem; Vincent P Kelly
Journal:  Nutrients       Date:  2015-04-15       Impact factor: 5.717

5.  HIV-1 Subtypes and 5'LTR-Leader Sequence Variants Correlate with Seroconversion Status in Pumwani Sex Worker Cohort.

Authors:  Raghavan Sampathkumar; Joel Scott-Herridge; Binhua Liang; Joshua Kimani; Francis A Plummer; Ma Luo
Journal:  Viruses       Date:  2017-12-23       Impact factor: 5.048

6.  Low-level alternative tRNA priming of reverse transcription of HIV-1 and SIV in vivo.

Authors:  Christine M Fennessey; Celine Camus; Taina T Immonen; Carolyn Reid; Frank Maldarelli; Jeffrey D Lifson; Brandon F Keele
Journal:  Retrovirology       Date:  2019-04-04       Impact factor: 4.602

Review 7.  Exploiting tRNAs to Boost Virulence.

Authors:  Suki Albers; Andreas Czech
Journal:  Life (Basel)       Date:  2016-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.